Rearranged during transfection (RET) is involved in the physiological development of some organ systems. Activating RET alterations via either gene fusions or point mutations are potent oncogenic drivers in non-small cell lung cancer, thyroid cancer, and in multiple diverse cancers. RET-altered cancers were initially treated with multikinase inhibitors (MKIs). The efficacy of MKIs was modest at the expense of notable toxicities from their off-target activity.
AST 487
From $100
Lenvatinib
From $80
Lenvatinib Mesylate
From $80
LUN09945
From $82
MP-470
From $90
Regorafenib
From $75
Regorafenib (BAY 73-4506)
From $95
Regorafenib Hydrochloride
From $80
TG101209
From $80
WHI-P180
From $131
WHI-P180 Hydrochloride
From $125